fenofibrate has been researched along with Autoimmune Diabetes in 14 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 9.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 5.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| " Finally, we treated NOD mice with fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes development." | 3.88 | Abnormal islet sphingolipid metabolism in type 1 diabetes. ( Buschard, K; Claessens, LA; Dahl-Jørgensen, K; Gerling, IC; Hanssen, KF; Hasselby, JP; Holm, LJ; Kaur, S; Koeleman, BPC; Krogvold, L; Mathews, CE; Morgan, NG; Pociot, F; Roep, BO; Russell, MA, 2018) |
| "Fenofibrate-treated NOD mice had a more stable blood glucose, which was associated with reduced non-fasting and increased fasting blood glucose." | 1.51 | Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice. ( Bilgin, M; Buschard, K; Giacobini, JD; Hasselby, JP; Haupt-Jorgensen, M; Holm, LJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kataoka, SY | 1 |
| Lois, N | 1 |
| Kawano, S | 1 |
| Kataoka, Y | 1 |
| Inoue, K | 1 |
| Watanabe, N | 1 |
| Holm, LJ | 2 |
| Haupt-Jorgensen, M | 1 |
| Giacobini, JD | 1 |
| Hasselby, JP | 2 |
| Bilgin, M | 1 |
| Buschard, K | 2 |
| Abdel-Aziz, AM | 1 |
| Abozaid, SMM | 1 |
| Yousef, RKM | 1 |
| Mohammed, MM | 1 |
| Khalaf, HM | 1 |
| Krogvold, L | 1 |
| Kaur, S | 1 |
| Claessens, LA | 1 |
| Russell, MA | 1 |
| Mathews, CE | 1 |
| Hanssen, KF | 1 |
| Morgan, NG | 1 |
| Koeleman, BPC | 1 |
| Roep, BO | 1 |
| Gerling, IC | 1 |
| Pociot, F | 1 |
| Dahl-Jørgensen, K | 1 |
| Pearsall, EA | 1 |
| Cheng, R | 2 |
| Matsuzaki, S | 1 |
| Zhou, K | 1 |
| Ding, L | 1 |
| Ahn, B | 1 |
| Kinter, M | 1 |
| Humphries, KM | 1 |
| Quiambao, AB | 1 |
| Farjo, RA | 1 |
| Ma, JX | 2 |
| Chahande, S | 1 |
| Murthy, R | 1 |
| Zhang, J | 1 |
| Cheng, Y | 1 |
| Gu, J | 1 |
| Wang, S | 1 |
| Zhou, S | 1 |
| Wang, Y | 1 |
| Tan, Y | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Mellen, N | 1 |
| Ma, J | 1 |
| Zhang, C | 1 |
| Li, Z | 1 |
| Cai, L | 1 |
| Simó, R | 1 |
| Hernández, C | 1 |
| Hermans, MP | 1 |
| Chen, Y | 1 |
| Hu, Y | 1 |
| Lin, M | 1 |
| Jenkins, AJ | 1 |
| Keech, AC | 1 |
| Mott, R | 1 |
| Lyons, TJ | 1 |
| Abcouwer, SF | 1 |
| Engelen, W | 1 |
| Manuel-y-Keenoy, B | 1 |
| Vertommen, J | 1 |
| De Leeuw, I | 1 |
| Van Gaal, L | 1 |
| Letonturier, P | 1 |
| Hajós, P | 1 |
| Tornyossi, M | 1 |
3 reviews available for fenofibrate and Autoimmune Diabetes
| Article | Year |
|---|---|
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Mac | 2023 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Evidence-Based Medicine; Fenofibrate; | 2011 |
1 trial available for fenofibrate and Autoimmune Diabetes
| Article | Year |
|---|---|
Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus.
Topics: Adult; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 1; Dosage Forms; Double-Blind Method | 2005 |
10 other studies available for fenofibrate and Autoimmune Diabetes
| Article | Year |
|---|---|
Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Fenofibrate; Homeostasis; Hypolipidemic A | 2019 |
Fenofibrate ameliorates testicular damage in rats with streptozotocin-induced type 1 diabetes: role of HO-1 and p38 MAPK.
Topics: Animals; Antioxidants; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Down-R | 2020 |
Abnormal islet sphingolipid metabolism in type 1 diabetes.
Topics: Adult; Animals; Autoimmunity; Case-Control Studies; Cell Proliferation; Cells, Cultured; Diabetes Me | 2018 |
Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Disease Models, Animal; Fenofib | 2019 |
Lipemia retinalis following systemic steroids for neurocysticercosis in a juvenile diabetic.
Topics: Adolescent; Anti-Inflammatory Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; | 2015 |
Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.
Topics: Animals; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2016 |
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
Topics: Animals; Capillary Permeability; Cell Adhesion; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dis | 2013 |
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PP | 2013 |
[Diabetes mellitus: types 1 & 2 increasingly similar].
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Mass Index; Child; Diabetes Complications; Diabetes Mel | 2006 |
Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fe | 1989 |